Net Income

With its Q4 earnings approaching, all eyes are on Federal Realty to see if its premium retail strategy can sustain its record dividend amid market shifts.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

With a $200M facility, BlackOpal's GemStone uses blockchain to offer institutional investors high-yield Brazilian assets without the traditional credit risk.

MiNK Therapeutics and UW–Madison launch a trial for an 'off-the-shelf' cell therapy, aiming to prevent deadly Graft-Versus-Host Disease (GvHD).

A new report reveals Canada's rail sector hit record safety, invested $4.5B, and grew its high-paying workforce, proving its essential economic role.

The pan-European exchange reports a year-over-year increase in December trading, with focus shifting to the impact of its recent Athens market acquisition.

After 13 years of refining its model, the luxury hair extension salon is partnering with a top developer to launch its specialized concept nationwide.

Singapore's Temasek injects another $150M into Roc360's REIT, highlighting a major institutional shift to real estate debt to fix America's aging houses.

As ENvue Medical prepares to ring the Nasdaq bell, a look at how its non-invasive tech for tube placement and pain relief is shaking up the MedTech world.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The fast-food giant launches 'Arches & Ambition' to rebrand its jobs as career launchpads, but how does it stack up against industry labor realities?

The dessert franchise touts record sales and coast-to-coast expansion, signaling a froyo comeback. But a closer look reveals a complex story of high hopes and financial risks.

A new report finds 90% of nurses miss key updates due to flawed communication, leading to patient care errors and fueling the nursing staff crisis.

The investment giant's new podcast season tackles the energy trilemma, exploring AI's power thirst, the return of nuclear, and fossil fuel's role.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new survey shows no firm recovers from cyberattacks in a day, with downtime lasting weeks. Yet, executive focus on resilience may be dangerously waning.

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.